B+
Bull case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
PRTA
ProthenaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+87.0
Score
AI commentary
The post-earnings tone is mildly constructive because of the cash balance, PADOVA publication, and continued partnered-program milestones, but the lower year-end cash midpoint offsets part of that benefit. The packet does not provide a verified post-release percentage move, analyst target changes, estimate revisions, or consensus surprise; social coverage is absent. This remains a monitoring-oriented, event-driven view rather than a high-conviction bullish thesis.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06catalystQ2 results reset cash outlookMedium impact
Q2 results showed $289.1 million of quarter-end cash and restricted cash, while updated year-end cash guidance is approximately $259 million midpoint after incorporating repurchases through July 30. The release also highlighted PADOVA results and continued partnered-program progress, but no verified consensus surprise or analyst revision is available [#SEC-8K-2026-08-06].
2026-12-31eventBMS decision on PRX019 advancementHigh impact
Bristol Myers Squibb may decide by year-end 2026 whether to advance PRX019. Advancement could generate a $55 million clinical milestone; a no-go or delay would remove that validation and cash catalyst [#SEC-8K-2026-08-06].
2029-12-31catalystPartnered clinical executionHigh impact
Roche’s approximately 900-participant PARAISO trial for prasinezumab and Novo Nordisk’s approximately 1,280-participant CLEOPATTRA trial for coramitug are expected to reach primary completion in 2029. BMS’s TargetTau-1 trial is expected to complete in the first half of 2027. These programs offer substantial optionality but carry high clinical and timing risk [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology